tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Chen CH et al. Comparison of tuberculosis infection rates in a national database of renal transplant patients with data from a single center in Taiwan. 2014 Transplant. Proc. pmid:24656019
Ferraresso M et al. Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750525
Garcia CD et al. Renal transplantation in children less than six years old. 2001 Nov-Dec Transplant. Proc. pmid:11750527
Mendez R FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636522
Kahl A et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. 1998 Transplant. Proc. pmid:9532149
Nazmul MN et al. Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. 2017 Transplant. Proc. pmid:29198681
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Suzuki K et al. Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy. 2000 Transplant. Proc. pmid:11119910
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Stock PG et al. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. 1993 Transplant. Proc. pmid:7679838
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Pedroso JA et al. Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy. 2014 Transplant. Proc. pmid:25242789
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Hachida M et al. Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. 1999 Transplant. Proc. pmid:10455968
Yoshimura N et al. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients. 1998 Transplant. Proc. pmid:9474949
Takeuchi H et al. Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. 1998 Transplant. Proc. pmid:9474950
Fukushima N et al. Role of endothelial apoptosis in delayed xenograft rejection in pig-to-baboon cardiac transplantation. 1999 Transplant. Proc. pmid:10578268
Comuzzi C et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. 2010 Transplant. Proc. pmid:20534291
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Basu A et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. 2005 Transplant. Proc. pmid:15848576
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Töz H et al. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies. 2004 Jan-Feb Transplant. Proc. pmid:15013324
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Marchewka Z et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. 2009 Transplant. Proc. pmid:19545703
Herrero MJ et al. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. 2010 Transplant. Proc. pmid:20970643
Bachetoni A et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. 2007 Jul-Aug Transplant. Proc. pmid:17692678
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Grossi P et al. Infectious complications in experimental small bowel transplantation. 1994 Transplant. Proc. pmid:7518155
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Tsugita M et al. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. 1995 Transplant. Proc. pmid:7533393
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Gaston RS Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. 1999 Transplant. Proc. pmid:10616556
Hoshinaga K et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. 2005 Transplant. Proc. pmid:15919457
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Sugitani A et al. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan. 2005 Transplant. Proc. pmid:15919459
Varo E et al. Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low dose tacrolimus and basiliximab. 2002 Transplant. Proc. pmid:12176471
Braun F et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. 2002 Transplant. Proc. pmid:12176473
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Hayes D et al. Aerosolized tacrolimus: a case report in a lung transplant recipient. 2010 Transplant. Proc. pmid:21094875
Braun F et al. How to handle mycophenolate mofetil in combination with tacrolimus? 1998 Transplant. Proc. pmid:9865309
Schorlemmer HU et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. 1998 Transplant. Proc. pmid:9865312
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Chamienia A et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. 2006 Jan-Feb Transplant. Proc. pmid:16504670
Gregory CR Immunosuppressive approaches to the prevention of graft vascular disease. 1998 Transplant. Proc. pmid:9595134
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Gentil MA et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. 2003 Transplant. Proc. pmid:12962766
Garcia I Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up. 2002 Transplant. Proc. pmid:12176516
Hattori R et al. FK 506 in cadaveric kidney transplantation from non-heart-beating donors. 1998 Transplant. Proc. pmid:9838666
Fischer L et al. Hepatitis G virus infection in liver transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083208
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Hsu KH et al. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. 2010 Transplant. Proc. pmid:20430208
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Moutabarrik A et al. Effect of FK 506 and cyclosporine on the expression of IL-6 and its receptor on stimulated monocytes. 1993 Transplant. Proc. pmid:7685949
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Mohacsi P et al. Immunosuppression in ABO-incompatible transplantation. 2001 Transplant. Proc. pmid:11377508
Artz MA et al. Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. 2002 Transplant. Proc. pmid:12176579
Saber LT et al. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. 2007 Transplant. Proc. pmid:18089330
Opelz G New immunosuppressants and HLA matching. 2001 Feb-Mar Transplant. Proc. pmid:11266911
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Chung YW et al. Tacrolimus-Induced Apoptosis is Mediated by Endoplasmic Reticulum-derived Calcium-dependent Caspases-3,-12 in Jurkat Cells. 2018 Transplant. Proc. pmid:29731088
Budde K et al. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 1998 Transplant. Proc. pmid:9723280
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Li Y et al. Long-term comparison of rat model of chronic allograft rejection of orthotopic small bowel transplantation induced by cyclosporine versus tacrolimus. 2013 Transplant. Proc. pmid:23769050
Zeevi A et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. 1987 Transplant. Proc. pmid:2445073
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Ishida S et al. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104127
Asensio M et al. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. 2002 Transplant. Proc. pmid:12176650
Kandaswamy R et al. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation? 2008 Transplant. Proc. pmid:18374118
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Sperschneider H A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267291
Mühlbacher F Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. 2001 Feb-Mar Transplant. Proc. pmid:11267317
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Martins L et al. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. 2000 Transplant. Proc. pmid:11134735
Nardo B et al. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. 2000 Transplant. Proc. pmid:11134771
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Nichelle L et al. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral. 2002 Transplant. Proc. pmid:12431623
Ciancio G et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. 2010 Transplant. Proc. pmid:21094804
Lo A et al. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. 2001 Feb-Mar Transplant. Proc. pmid:11267516
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020